Literature DB >> 24657266

Inhibitory effect of Disulfiram/copper complex on non-small cell lung cancer cells.

Lincan Duan1, Hongmei Shen2, Guangqiang Zhao1, Runxiang Yang3, Xinyi Cai4, Lijuan Zhang5, Congguo Jin6, Yunchao Huang7.   

Abstract

Non-small cell lung cancer (NSCLC) is the most common cause of cancer-related death in both men and women worldwide. Recently, Disulfiram has been reported to be able to inhibit glioblastoma, prostate, or breast cancer cell proliferation. In this study, the synergistic effect of Disulfiram and copper on NSCLC cell growth was investigated. Inhibition of cancer cell proliferation was detected by 1-(4,5-Dimethylthiazol-2-yl)-3,5-diphenylformazan (MTT) assay and cell cycle analysis. Liquid colony formation and tumor spheroid formation assays were used to evaluate their effect on cancer cell clonogenicity. Real-time PCR was performed to test the mRNA level of cancer stem cell related genes. We found that Disulfiram or copper alone did not potently inhibit NSCLC cell proliferation in vitro. However, the presence of copper significantly enhanced inhibitory effect of Disulfiram on NSCLC cell growth, indicating a synergistic effect between Disulfiram and copper. Cell cycle analysis showed that Disulfiram/copper complex caused NSCLC cell cycle arrest in G2/M phase. Furthermore, Disulfiram/copper significantly increased the sensitivity of cisplatin in NSCLC cells tested by MTT assay. Liquid colony formation assay revealed that copper dramatically increased the inhibitory effect of Disulfiram on NSCLC cell colony forming ability. Disulfiram combined with copper significantly attenuated NSCLC cell spheroid formation and recuded the mRNA expression of lung cancer stem cell related genes. Our data suggest that Disulfiram/copper complex alone or combined with other chemotherapy is a potential therapeutic strategy for NSCLC patients.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Copper; Disulfiram; MTT; NSCLC; Spheroids

Mesh:

Substances:

Year:  2014        PMID: 24657266     DOI: 10.1016/j.bbrc.2014.03.047

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  32 in total

1.  Aldehyde dehydrogenase activity plays no functional role in stem cell-like properties in anaplastic thyroid cancer cell lines.

Authors:  Mika Shimamura; Tomomi Kurashige; Norisato Mitsutake; Yuji Nagayama
Journal:  Endocrine       Date:  2016-12-31       Impact factor: 3.633

2.  Membrane Loaded Copper Oleate PEGylated Liposome Combined with Disulfiram for Improving Synergistic Antitumor Effect In Vivo.

Authors:  Lingli Zhou; Liu Yang; Chulei Yang; Yi Liu; Qiuyue Chen; Wenli Pan; Qing Cai; Lifeng Luo; Lu Liu; Shan Jiang; Haibing He; Yu Zhang; Tian Yin; Xing Tang
Journal:  Pharm Res       Date:  2018-05-23       Impact factor: 4.200

3.  Disulfiram causes selective hypoxic cancer cell toxicity and radio-chemo-sensitization via redox cycling of copper.

Authors:  Kelly C Falls-Hubert; Aimee L Butler; Kai Gui; Michael Anderson; Mengshi Li; Jeffrey M Stolwijk; Samuel N Rodman; Shane R Solst; Ann Tomanek-Chalkley; Charles C Searby; Val C Sheffield; Vanessa Sandfort; Hartmut Schmidt; Michael L McCormick; Brian R Wels; Bryan G Allen; Garry R Buettner; Michael K Schultz; Douglas R Spitz
Journal:  Free Radic Biol Med       Date:  2020-02-04       Impact factor: 7.376

Review 4.  Recent Advances in Antabuse (Disulfiram): The Importance of its Metal-binding Ability to its Anticancer Activity.

Authors:  Maricela Viola-Rhenals; Kush R Patel; Laura Jaimes-Santamaria; Guojun Wu; Jinbao Liu; Q Ping Dou
Journal:  Curr Med Chem       Date:  2018-02-12       Impact factor: 4.530

5.  Mouse pharmacokinetics and metabolism of the phenylurea thiocarbamate NSC 161128.

Authors:  Emily J Koubek; Rachel A Kudgus; Chad A Walden; Renee M McGovern; Joseph M Covey; Matthew M Ames; Joel M Reid
Journal:  Cancer Chemother Pharmacol       Date:  2022-07-27       Impact factor: 3.288

Review 6.  Recent advances in the delivery of disulfiram: a critical analysis of promising approaches to improve its pharmacokinetic profile and anticancer efficacy.

Authors:  Muhammad Asim Farooq; Md Aquib; Daulat Haleem Khan; Zahid Hussain; Anam Ahsan; Mirza Muhammad Faran Ashraf Baig; Dickson Pius Wande; Muhammad Masood Ahmad; Hafiz Muhammad Ahsan; Jiang Jiajie; Bo Wang
Journal:  Daru       Date:  2019-11-22       Impact factor: 3.117

Review 7.  Current progress and future perspectives of polypharmacology : From the view of non-small cell lung cancer.

Authors:  Ramanathan Karuppasamy; Shanthi Veerappapillai; Sayoni Maiti; Woong-Hee Shin; Daisuke Kihara
Journal:  Semin Cancer Biol       Date:  2019-11-04       Impact factor: 17.012

8.  Delivery of disulfiram into breast cancer cells using folate-receptor-targeted PLGA-PEG nanoparticles: in vitro and in vivo investigations.

Authors:  Hamidreza Fasehee; Rassoul Dinarvand; Ardeshir Ghavamzadeh; Mehdi Esfandyari-Manesh; Hanieh Moradian; Shahab Faghihi; Seyed Hamidollah Ghaffari
Journal:  J Nanobiotechnology       Date:  2016-04-21       Impact factor: 10.435

Review 9.  Spelling Out CICs: A Multi-Organ Examination of the Contributions of Cancer Initiating Cells' Role in Tumor Progression.

Authors:  Shivani Baisiwala; Shreya Budhiraja; Chirag Goel; Khizar R Nandoliya; Miranda R Saathoff; Atique U Ahmed
Journal:  Stem Cell Rev Rep       Date:  2021-07-09       Impact factor: 6.692

10.  CUSP9* treatment protocol for recurrent glioblastoma: aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, sertraline augmenting continuous low dose temozolomide.

Authors:  Richard E Kast; Georg Karpel-Massler; Marc-Eric Halatsch
Journal:  Oncotarget       Date:  2014-09-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.